TORONTO, Feb. 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that its annual audited financial statements for the fiscal year ended November 30, 2022, related management's discussion and analysis and accompanying Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2022 (collectively, the "Required Filings") due February 28, 2023 (the "Filing Deadline") will not be filed by the Filing Deadline.
Read more at newswire.caIntellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
